JPMorgan downgraded Pliant Therapeutics (PLRX) to Underweight from Neutral without a price target The firm says the investment story “has remained in limbo” since the bexotegrast program for idiopathic pulmonary fibrosis was discontinued earlier this year. Pliant is weighing multiple strategic direction, from in-licensing new clinical-stage assets to merging with another biotech, the analyst tells investors in a research note. JPMorgan believes the company “remains in a holding pattern” pending news on next steps.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX: